LDN Social Media
Get connected with us on social networks
Combination therapy: A New Tool for the Management of Obesity
Endocr Metab Immune Disord Drug Targets
25 August 2023
https://pubmed.ncbi.nlm.nih.gov/37641995/
Obesity is a long-term lifestyle problem that can lead to disastrous consequences. Lifestyle interventions are one of the initial lines of management strategies for obesity but in long term, it is not very effective in the management of obesity. Some people also manage their weight with bariatric surgery, which is now the most effective obesity treatment. Synthetic pharmaceuticals make a bridge between lifestyle modification and bariatric surgery-based obesity management. The major problem associated with monotherapy without side effects is that these are moderately effective and also need in higher doses. The combination therapy is already used for many serious and complicated disease treatments and management and has shown efficacy as well. Generally, we use two or more medicines with different of actions for a better effect. The commonly used combination therapy for obesity management includes low-dose phentermine and prolonged and slow-releasing mechanism topiramate; naltrexone along with bupropion. Phentermine with inhibitors of Na-glucose cotransporter-2 or glucagon-like peptide-1 (GLP-1) agonist with gastric hormone or Na-glucose cotransporter-2 is two more viable combo therapy. This combination strategy aims to achieve success in the bariatric surgery and the scientific community is working in this direction.
Keywords: Obesity; glucagon; liraglutide; lorcaserin; orlistat; phentermine